SCHEMBL5537868

SCHEMBL5537868

C[CH]N1CCCc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.50
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MGLL Q99685 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
TSHR P16473 1/20 0.47
MAPT P10636 3/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
RECQL P46063 1/20 0.42
HTT P42858 2/20 0.41
USP2 O75604 1/20 0.41
CDK4 P11802 1/20 0.41
ALOX15 P16050 1/20 0.41
CCND1 P24385 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198901 0.88 ALDH1A1 (0.50) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL28674863 0.81 SMN1; SMN2 (0.49) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL9217182 0.81 SMN1; SMN2 (0.49) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29522795 0.81 SMN1; SMN2 (0.53) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL94509 0.81 SMN1; SMN2 (0.53) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL27570415 0.79 SMN1; SMN2 (0.51) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL16340761 0.76 SMN1; SMN2 (0.47) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4365887 0.75 ALDH1A1 (0.44) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL8975430 0.74 SMN1; SMN2 (0.46) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29699544 0.74 ALDH1A1 (0.58) NOTUMMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOTUM 3827/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.